- Home
- KROS
as 02-04-2025 4:00pm EST
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 460.6M | IPO Year: | 2020 |
| Target Price: | $45.33 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.78 - $73.00 | Next Earning Date: | 02-26-2025 |
| Revenue: | $651,000 | Revenue Growth: | 8037.50% |
| Revenue Growth (this year): | 303.27% | Revenue Growth (next year): | -89.95% |
Latest Keros Therapeutics Inc. News
KROS Breaking Stock News: Dive into KROS Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
Simply Wall St.
8 days ago
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation
Zacks
13 days ago
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why
Zacks
14 days ago
Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?
MT Newswires
15 days ago
Keros to Receive $200 Million From Takeda In Connection to Elritercept License Deal
MT Newswires
15 days ago
Cantor Fitzgerald Downgrades Keros Therapeutics to Neutral From Overweight
GlobeNewswire
15 days ago
Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept
Zacks
16 days ago
Down -36.23% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround
Compare KROS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KROS Keros Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.